This post is presented by our media partner Psychedelic News Wire
View the original article here.
The U.S. Drug Enforcement Administration (DEA) recently announced new production quotas for controlled substances under schedules 1 and 2. The new quotas show increases in the supply of psychedelics such as ibogaine, psilocybin and psilocyn, which the federal agency notes shall be used for research purposes.
Specifically, the 2024 quotas for psilocyn and psilocybin have risen to 36,000 grams and 30,000 grams respectively. Ibogaine’s quota has also risen, from 150 grams to 210 grams, to help meet the increasing demand for research.
The agency’s increased focus on the production of psychedelics comes at a time when more anecdotal reports and studies are highlighting the potential these substances have in managing various mental-health conditions. For instance, studies have found that ibogaine may be useful in treating addiction. Advocates and researchers are calling for the DEA to support further studies on the substance.
In its statement, the DEA added that it remained committed to ensuring that all patients with legitimate medical needs can access prescribed drugs.
Cannabis production quotas remain unchanged, however, with the DEA maintaining its aggregate quota of 6.6 million grams since 2023. Quotas for other drugs such as mescaline, LSD, MDMA and DMT also remain the same.
This stability in marijuana production quotas comes as the agency prepares to decide on its rescheduling in December. This comes after it was recommended that the drug be rescheduled to schedule 3. Other substances under this schedule include ketamine and anabolic steroids.
Currently, cannabis is classified under schedule 1 of the Controlled Substances Act. Drugs under this classification are said to have no accepted medical use along with a high potential for abuse. If the drug is rescheduled, it could change how scientists access the drug for research, eliminating it from the aggregate production quota process.
A recent report by the Congressional Research Service notes that rescheduling may not eliminate all barriers in research, however. The report explains that researchers and drug sponsors of cannabis or CBD-containing drugs can only benefit from looser restrictions linked to rescheduling if congressional action is taken.
In other news, the DEA is expected to take part in a hearing involving a proposed ban on DOC and DOI. The two psychedelic compounds are analogs of DOM, a hallucinogen classified under schedule 1. These compounds act on an individual’s central nervous system and are highly selective agonists for serotonin 2 receptors in the brain.
The 10-day hearing comes after a lawsuit that challenged the scheduling process for these compounds was dismissed by a federal court.
These increasing production quotas for psychedelics suggest that more companies are joining the likes of Compass Pathways PLC (NASDAQ: CMPS) in studying hallucinogens with a view to leveraging their therapeutic potential.
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com
PsychedelicNewsWire is powered by IBN
This post was originally published by our media partner here.
